๐งช NEW DRUG DEVELOPMENT AND PRECLINICAL TOXICITY STUDIES
By Dr. Sk Sabir Rahaman, MBBS, MD (Pharmacology), DFM(Family Medicine), FCFM, CCEBDM, CCLSD
๐ INTRODUCTION: WHY STUDY DRUGS BEFORE HUMAN USE?
Before a new drug is tested in humans, it must undergo preclinical studies in laboratory animals. These studies are done to:
-
Establish scientific rationale for safety
-
Determine safe dose ranges and routes of administration
-
Predict potential toxicities and side effects in humans
-
Comply with regulatory and ethical standards (GCP, GLP, CPCSEA/CCSEA guidelines in India)
⚖️ The ultimate goal: Protect human participants when clinical trials begin.
๐ TYPES OF PRECLINICAL TOXICITY STUDIES
✅ General Rule: Preclinical toxicity testing must be done in two animal species — one rodent (rat/mouse) and one non-rodent (dog/monkey), using the intended human route (oral, IV, inhalation, etc.).
1. Acute Toxicity Studies
-
Purpose: To determine LD₅₀ (median lethal dose) and identify immediate toxic effects.
-
Method:
-
Animals receive a single dose or graded doses.
-
Monitored for 24–72 hours for mortality and clinical signs.
-
-
Outcome: Defines the safety margin and helps select the starting human dose (usually 1/100th of LD₅₀ in animals).
-
Example: A drug with LD₅₀ = 200 mg/kg in rats → starting human dose ≈ 2 mg/kg.
2. Subacute (Repeated-Dose) Toxicity Studies
-
Purpose: Detect cumulative toxicity and target organ damage.
-
Duration: 14–28 days.
-
Parameters Monitored:
-
Body weight, food/water intake
-
Hematology (Hb, WBCs), Biochemistry (liver enzymes, kidney function)
-
Histopathology of vital organs (liver, kidney, heart, lungs, etc.)
-
-
Outcome: Establishes:
-
Maximum Tolerated Dose (MTD)
-
No Observed Adverse Effect Level (NOAEL)
-
-
Clinical Tip: If hepatotoxicity appears in rats, then LFTs are monitored closely in Phase I human trials.
3. Chronic Toxicity Studies
-
Purpose: Assess long-term safety and simulate chronic human use.
-
Duration: 6–12 months (sometimes longer depending on intended therapy).
-
Animals: One rodent + one non-rodent species.
-
Monitoring: Same as subacute, but with more focus on:
-
Organ damage
-
Carcinogenic potential
-
Cumulative effects of repeated dosing
-
-
Example: Chronic NSAID exposure → renal papillary necrosis in animals → routine renal monitoring in patients.
4. Special Toxicity Studies
These assess genetic, reproductive, and developmental risks:
| Type | Purpose | Common Tests |
|---|---|---|
| Mutagenicity | DNA mutations & chromosomal damage | Ames test, chromosomal assays |
| Carcinogenicity | Detect cancer-causing potential | 2-year rodent studies |
| Teratogenicity | Fetal malformations (birth defects) | Administered to pregnant animals |
| Reproductive Toxicity | Fertility, pregnancy, lactation effects | Pre-mating to lactation studies |
⚠️ Clinical Application: The thalidomide tragedy (causing birth defects) → made teratogenicity testing mandatory worldwide.
๐ HOW THESE STUDIES GUIDE HUMAN TRIALS
| Study Type | Human Application |
|---|---|
| Acute Toxicity | Sets initial human dose and emergency safety guidelines |
| Subacute Toxicity | Defines short-term therapeutic window |
| Chronic Toxicity | Essential for chronic diseases (HTN, diabetes, epilepsy) |
| Special Toxicity | Guides use in pregnancy, pediatrics, cancer therapy |
⚖️ REGULATORY & ETHICAL FRAMEWORK (INDIA)
-
Preclinical studies must follow Good Laboratory Practice (GLP).
-
Ethical oversight by CCSEA (formerly CPCSEA – Committee for the Control and Supervision of Experiments on Animals), Ministry of Environment, Forest & Climate Change, Govt. of India.
-
Mandatory approvals before starting:
-
Institutional Animal Ethics Committee (IAEC) approval
-
CCSEA registration of animal house
-
-
Only after preclinical package (toxicity + pharmacology) is complete → IND (Investigational New Drug) application is submitted to DCGI (CDSCO) for human trials.
๐ SUMMARY
-
Preclinical toxicity studies are mandatory before clinical trials.
-
Include acute, subacute, chronic, and special tests in at least two animal species.
-
Outcomes: MTD, NOAEL, organ-specific risks.
-
Guide dose selection, patient monitoring, and trial design.
-
Governed by GLP, IAEC, and CCSEA regulations in India.
๐ Visit My Website for Articles & other Free PDFs and Resources
Comments
Post a Comment